EU: resistant Klebsiella bloodstream infection rate up 72% since 2019
ECDC’s report for 2025 shows that two EU targets for 2030 are off track. The findings concern specific bacteria and antibiotics.

The estimated EU rate of bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae reached 3.75 per 100,000 people in 2025, according to ECDC’s report published on 18 November. That is 72% above the 2019 baseline, against a target of a 5% reduction by 2030.
For E. coli resistant to third-generation cephalosporins, the corresponding rate reached 12.13 per 100,000, up 16.4% from 2019. The rate for meticillin-resistant Staphylococcus aureus (MRSA) was 4.56, down 19% from 2019. The EU target for 2030 had been reached in 2025, although the rate has risen in the last two years.
Across the wider WHO European Region, at least half the Klebsiella samples tested in 21 of the 43 reporting countries were resistant to third-generation cephalosporins. These are laboratory findings, not a percentage of all patients or measured treatment failures.
The joint WHO/Europe–ECDC analysis combines 2025 data from bacteria found in blood and cerebrospinal fluid. National surveillance systems differ, so country comparisons require caution. The organisations call for stronger hospital infection prevention, laboratory testing and careful antibiotic use.
English translation of the Greek edition · Read in Greek